Jpmorgan Chase & CO Hille Vax, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Hille Vax, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,027 shares of HLVX stock, worth $27,633. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,027
Previous 33,402
58.01%
Holding current value
$27,633
Previous $482,000
95.02%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding HLVX
# of Institutions
78Shares Held
36.1MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$20.9 Million1.01% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$9.69 Million0.74% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$4.12 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$3.86 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.71 Million0.06% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $65.9M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.